Mario Sznol, MD, on Patient Selection for Combination Therapy in mRCC

Commentary
Video

Mario Sznol, MD, professor of medicine, co-director, Yale SPORE in Skin Cancer, Yale Cancer Center, discusses patient selection for combination therapy in metastatic renal cell carcinoma.

Mario Sznol, MD, professor of medicine, co-director, Yale SPORE in Skin Cancer, Yale Cancer Center, discusses patient selection for combination therapy in metastatic renal cell carcinoma (mRCC).

The combination of ipilimumab (Yervoy) plus nivolumab (Opdivo) has not yet been compared head-to-head with anti—PD-1/VEGF TKI combinations, so it is not clear which approach is better, Sznol says. Moreover, the patient demographics were slightly different in the studies that pushed these regimens to the forefront. It is not sufficient to say that a particular regimen is better based solely on 1-year overall survival data, he adds.

Sznol says clinicians should look at individual subgroups of patients with mRCC stratified by risk, based on either the International Metastatic Renal Cell Carcinoma Database Consortium or Motzer criteria. It is probably best to look at PD-L1 expression, too. Sznol notes that he would give a PD-L1—negative patient with good-risk disease a PD-1 inhibitor plus a VEGF TKI, but would otherwise give ipilimumab plus nivolumab in the frontline setting.

Recent Videos
Manali Kamdar, MD, on Liso-Cel's Ongoing Benefit in the Treatment Lanscape for LBCL
Steve Kanner, PhD, the chief scientific officer of Caribou Biosciences
David Dimmock, MBBS, on AI-Guided ASO Development for Ultra-Rare Diseases
Manali Kamdar, MD, on The Importance of Bringing Liso-Cel to Earlier Lines of Lymphoma Treatment
Subhash Tripathi, PhD, on Generating In Vivo CARs With A2-CAR-CISC EngTreg Cells
Luke Roberts, MBBS, PhD, on Challenges in Developing Gene Therapy for Heart Failure
Steve Kanner, PhD, the chief scientific officer of Caribou Biosciences
Paul Y. Song, MD, the chairman and chief executive officer of NKGen
Lisa Nieland on Slowing Tumor Growth in Glioblastoma With Novel AAV Therapy
Manali Kamdar, MD, on Acclimating to Routine CAR T Practice in the Field
© 2024 MJH Life Sciences

All rights reserved.